China Resources Pharmaceutical Group Ltd.
3320
Rang in Aktien
#4218
China Resources Pharmaceutical Group Limited, an investment holding company,... China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Aktienkurs
$0.60125328
Marktkapitalisierung
$3.78B
Veränderung (1 Tag)
2.06%
Veränderung (1 Jahr)
-1.67%
Land
HK
Handel China Resources Pharmaceutical Group Ltd. (3320)
Kategorie
Healthcare
Operative Marge für China Resources Pharmaceutical Group Ltd. (3320)
Operative Marge zum October 2026 TTM: 4.21%
Laut den neuesten Finanzberichten und dem Aktienkurs von China Resources Pharmaceutical Group Ltd. beträgt die aktuelle operative Marge (TTM) 4.21%. Am Ende des Jahres 2023 lag die operative Marge bei 4.31%.
Historie der operativen Marge von China Resources Pharmaceutical Group Ltd. von 2013 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 4.21% | -10.43% |
| 2024 | 4.70% | 9.05% |
| 2023 | 4.31% | 1.17% |
| 2022 | 4.26% | 8.95% |
| 2021 | 3.91% | -7.57% |
| 2020 | 4.23% | 7.91% |
| 2019 | 3.92% | -28.86% |
| 2018 | 5.51% | 2.42% |
| 2017 | 5.38% | 1.32% |
| 2016 | 5.31% | -1.30% |
| 2015 | 5.38% | -17.48% |
| 2014 | 6.52% | -10.44% |
| 2013 | 7.28% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 62.34% | -85.19% |
US
|
|
| 0.00% | - |
SE
|
|
| 0.00% | - |
FR
|
|
| 0.00% | - |
IT
|
|
| 29.76% | -92.93% |
HK
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.